Home Bronchitis Look Behind the Curtain
SimplifyYourCold.com · Russell W. Raskin, MD

Your Favorite Pack of Antibiotics Is Essentially Dead

The five-day azithromycin prescription has been one of the most recognized in American medicine for decades. You or someone you know has received it. The reflex is deeply embedded: get sick, go see a doctor, come home with the pack.

Here is the problem. For the colds, chest colds and sinus symptoms that prescription often gets written for, no antibiotic is needed at all. When one is needed, a different antibiotic is usually the better choice. This is not a fringe opinion. It's where the major guidelines have stood for years.

Why You Think You Need This

You're not wrong for thinking you need this. Decades of prescribing patterns have shaped that belief — one prescription at a time, for generations of people who got better and concluded the antibiotic was responsible. If what you had was a cold, you didn't need the antibiotic, and it still carried risks. For the full story of how that belief was built, see Look Behind the Curtain. Here's a brief look at some common situations where this prescription still gets written most often.

Sore Throat

If your sore throat is bacterial, penicillin and amoxicillin have seventy years of evidence behind them. Azithromycin is a last resort, generally reserved for certain penicillin allergies, and even then, guidelines name options with stronger evidence behind them, and strep resistance to it is well known. Most sore throats are viral anyway. No antibiotic helps a viral sore throat.

Ear Infection

Better options than this one have existed for years. For ear infections in children, amoxicillin is the usual first choice, and for penicillin allergy, guidelines point to other antibiotics ahead of azithromycin. For many children with mild symptoms, especially those 2 and older, watching and waiting is an accepted first step. The youngest are usually treated right away.

Sinus Infection

Bacterial sinusitis is far rarer than it's diagnosed. Even when it genuinely is bacterial, current guidelines prefer watching and waiting first for many adults with uncomplicated symptoms, with symptom care in the meantime and a plan to follow up. If an antibiotic does become appropriate, guidelines don't recommend this one. Resistance is high, and better choices exist, with amoxicillin usually first. Its label lists only a three-day course for sinus infections. In my view, the five-day pack has no place here.

Cough & Bronchitis

For a chest cold or uncomplicated bronchitis, antibiotics make little to no difference. The best the studies could show was about half a day less cough, at the end of an illness that was already ending, and a real increase in side effects. The prescription still exists partly because people expect it. That expectation is not an acceptable reason to prescribe.

For full clinical details, see the clinician version.

If You Have One of the Uncommon Conditions It Actually Treats

Azithromycin has a legitimate role in specific, uncommon lower respiratory tract infections — the kind caused by organisms called atypicals, in confirmed pneumonias. Not colds. Not routine coughs. Not sinus infections. Even then, azithromycin is not the first drug your doctor should be reaching for.

R.W. Raskinism

You don't need an antibiotic for a cold. You need a plan.

Being informed changes the visit. If you leave an appointment with a five-day azithromycin prescription for a sore throat, a cough, or a sinus infection in 2026, you now have what the system was never designed to give you: the information to ask whether that decision was right.

Your doctor should be getting this right. Now you'll know when they may not be.
A cold is a viral illness, not a bacterial infection. Antibiotics don't treat viruses or the symptoms they cause. If you believe you may have a bacterial infection, seek medical evaluation promptly.

If you get this prescription for a cold, a cough or a sinus infection, it's fair to ask your clinician why. If it keeps coming, a second opinion is a reasonable next step.

For informational and educational purposes only. Does not constitute medical advice.

Clinical Perspective · Antibiotic Stewardship

Your Favorite Pack of Antibiotics Is Essentially Dead

Stop Writing This. The Evidence Made the Decision Years Ago.

Let me be precise about what I mean by essentially.

The five-day azithromycin regimen still exists. The molecule still works — in specific, narrow, well-defined situations. But as a general-purpose intervention for the sick adult in the urgent care exam room? That regimen is done. It's been done for years. Many providers haven't noticed. Most were likely trained on outdated protocols and never had a reason to revisit them.

There is the visit to a PCP, urgent care, or emergency room, for reasons far short of a true emergency, by patients who have often already decided what they need before they walk through the door. And there are the providers who oblige them, because the conversation takes time they don't have, because the patient pushes back, because a prescription is easier than an explanation. Then telemedicine arrived and completed the transformation. What was once a clinical encounter became a transaction. A prescription vending machine, available around the clock, no exam required. The patient feels served. The provider clears the queue. The antibiotic was never the point. The throughput was. For a full accounting of how this system was built, see Look Behind the Curtain.

I have also seen antibiotics marketed to the public like peace of mind in a box, something to keep at home and take at your own discretion. The cultural normalization of antibiotic self-prescribing is not a side effect of this system. It is the system working as designed.

It Seemed of Benefit

I was trained to write it. Early in my career it seemed more than reasonable — it seemed of benefit. The coverage was broad, the tolerability was good, the patients left with something. Then the science got clearer. When the evidence changed, I changed.

The Format Was Marketing

There was a time when nothing was easier to write for. The regimen fit the workflow perfectly. It had its own branded identity and its own patient demand by name. In my view, the form factor was marketing. A pill is a pill, but the packaging and the cultural moment made it feel like the modern choice. A three-day version came along, and in my experience it never caught on the way the five-day pack had. The five-day format had already won the culture. That moment has passed. The science moved. The prescribing hasn't. Not yet.

Upper Respiratory Is Not Lower Respiratory

Here is where we need to draw a line precisely. Upper respiratory tract infections — pharyngitis, otitis media, sinusitis, bronchitis — are a different conversation entirely from lower respiratory tract infections, which means pneumonia. The five-day regimen lives culturally in the URI space. That is where the damage is done. That is where this argument belongs. And as we will address shortly, the damage extends beyond URIs — the molecule has lost ground even where it once had firm standing. That is also where patient education can do real work: a clear explanation of the illness and a plan for the symptoms, with no prescription needed. In my view, that makes the five-day regimen not only hard to defend on the evidence, but unnecessary for most of these patients.

What This Regimen Was Never Supposed to Cover

The cultural identity of this regimen obscures what was always true about it: it was never indicated for the most common presentations that drive its prescription.

Never indicated — never was
  • Colds
  • Acute bronchitis
  • Acute sinusitis — no longer indicated as initial therapy (2025 AAO-HNS)
  • “Just in case” — this was never an indication
R.W. Raskinism

Just in case what?

What It Is Actually For

There are real indications. Azithromycin retains genuine clinical utility in a specific and narrow list of situations.

Valid indications — 2026
  • Pertussis
  • Select sexually transmitted infections — adherence-driven
  • Atypical CAP — adjunctive with beta-lactam in hospitalized patients
  • COPD exacerbation prophylaxis — confirmed by 2026 GOLD guidelines
  • Non-CF bronchiectasis — frequent exacerbators, after NTM exclusion
  • Traveler's diarrhea

That is a short and specific list. None of it is the patient sitting across from you with five days of congestion and colored mucus. Yellow, green, or brown — colored mucus is not a bacterial signal. It is an immune system signal. The distinction matters every time your patient correlates color with needing an antibiotic.

URIs: Indication by Indication

Pharyngitis

Azithromycin is not first-line. Penicillin and amoxicillin remain the standard for streptococcal disease. When penicillin allergy is present, cephalosporins and clindamycin are the preferred alternatives — both with superior evidence and better resistance profiles than azithromycin. If azithromycin must be used as a last resort in a penicillin-allergic patient, a three-day course would suffice. The five-day course has no defensible role here.

Otitis Media

The guidelines shifted years ago. High-dose amoxicillin is first line, with amoxicillin-clavulanate for specific situations. Azithromycin has a narrow role, for specific allergy scenarios. When azithromycin is warranted, a single dose or a three-day course are both supported options. The five-day regimen has no defensible role here.

Sinusitis

Bacterial sinusitis is continuously overdiagnosed. When the evidence overwhelmingly suggests secondary bacterial superinfection — not presumed, but supported by clinical findings — antibiotic therapy becomes reasonable. Even then, watchful waiting remains an accepted option under current guidelines, and saline, an intranasal steroid and pain relief belong in the plan either way. Azithromycin ranks even lower among antibiotic choices. Most providers skip straight to the antibiotic alone, bypassing the entire management framework. Overdiagnosis of bacterial sinusitis drives overuse of antibiotics that address neither the inflammation nor the obstruction patients actually need treated.

Bronchitis

Uncomplicated bronchitis — see full article. In acute bronchitis, antibiotics make little to no difference. Across 17 RCTs, the best result was about half a day less cough at the tail end of a self-limiting illness, with a meaningful increase in adverse events. That does not justify routine use. [10] In the rare setting of complicated bronchitis — COPD with suggested secondary bacterial infection — doxycycline is the better choice in most scenarios. Most bronchitis is viral and uncomplicated. Most prescriptions for the five-day regimen are unnecessary.

The Doxycycline Displacement

For patients who can swallow pills and have mature dentition — which is most patients over age twelve — in my view, Legionnaires' and pertussis aside, doxycycline is the superior alternative across nearly every outpatient indication where azithromycin is being considered. Better tissue penetration, better atypical organism coverage, superior resistance profile. There is no clinical reason to reflexively choose azithromycin when doxycycline is available and tolerated. For hospitalized community-acquired pneumonia, the evidence is less clear — recent data suggest equivalent or possibly superior outcomes with azithromycin alongside beta-lactam therapy. [7]

When doxycycline is truly contraindicated — pregnancy, young children, specific allergies — azithromycin becomes a reasonable choice. But that lane is narrow. If prescribing were aligned with evidence, azithromycin volume would drop by seventy-five to ninety percent, in my estimation. The reflex prescribing does not live in the legitimate indications. It lives everywhere else.

The Resistance Problem — Framed Correctly

I don't lead with resistance messaging when I talk to patients, and I won't lead with it here either. Research by Ritchie and colleagues demonstrated that patient-facing expectation-setting before the clinical encounter reduces the desire to receive antibiotics for a common cold. This platform exists precisely for that moment — an educated patient arrives at the visit already prepared.

But since we are speaking clinically: macrolide resistance has made this regimen unreliable for the organisms it was once trusted to cover. GAS macrolide resistance is rising. Macrolide-resistant Mycoplasma pneumoniae has become highly prevalent in parts of East Asia and the Western Pacific. [8] U.S. pneumococcal macrolide resistance now exceeds thirty percent. [9] The American Thoracic Society and IDSA responded accordingly: azithromycin monotherapy is no longer a first-line option for community-acquired pneumonia in the United States. It was an incredible tool. Haphazard prescribing for upper respiratory infections for decades devastated its utility — but not its use.

R.W. Raskinism

The molecule hasn't changed. What changed is everything we thought it covered.

What's Filling the Void

When this regimen became untenable, a vacuum formed. Some providers filled it with amoxicillin-clavulanate. Some with doxycycline. Some with an early course of prednisone. None of these are indicated for the basic URI either — and the steroid substitution concerns me as much as the antibiotic substitution.

What I think is actually happening: the providers doing this know their patients don't need antibiotics. They are not confused about the diagnosis. They are managing the visit — filling the space where the regimen used to go with something that feels like an intervention. The problem is not clinical reasoning. It is the vacuum.

And there is one more layer worth carrying with you: when that prescription happens to be a five-day azithromycin regimen, it is not just unnecessary. For a viral URI or acute bronchitis, it is the wrong drug for the wrong diagnosis. The “just in case” prescription failed on two levels simultaneously.

The Visit Itself as the Intervention

This is the argument I have been making for over thirteen years in urgent care. The consultation is not a delivery mechanism for a prescription. It is the intervention.

Expectation-setting — walking a patient through where they are in the arc of their illness, naming the phase, telling them what comes next — can dramatically reduce antibiotic prescribing without reducing patient satisfaction. In my experience, the reduction can be substantial. Harris et al., Annals of Internal Medicine, 2016 supports the framework.

The plan is the active ingredient. That is my clinical experience, and the communication research points the same way. In one study, parents who expected an antibiotic and didn't get one were more satisfied with the visit when the physician gave them a clear plan for what to do if their child didn't improve.

R.W. Raskinism

Your words matter more than you think. The plan is the active ingredient.

The Behavior Gap

Knowledge and behavior are not the same thing. The regimen persists because it is embedded in every layer of the system — the template you open, the patient's expectation, the attending's teaching, the path of least resistance in a system that rewards throughput over the practice of good medicine. Asking clinicians to pause, reconsider, and go deep on every prescription decision is a reasonable expectation that an unreasonable system makes seemingly impossible. Changing the evidence wasn't enough. For most, the workflow remained the same.

When a provider reaches for the five-day azithromycin regimen for a patient with an upper respiratory infection today, something remarkable is happening. An antibacterial agent is being prescribed for a condition we once believed warranted it — and have since learned does not. Even if the clinical picture convincingly suggested bacterial involvement, this would not be the correct choice today. The resistance profile alone disqualifies it. A superior alternative exists at every turn. And yet the prescription still gets written.

Plenty of providers know this. They write it anyway. I don't. You shouldn't. And the gap between knowing and doing is exactly what this platform exists to close.

The Scope of the Problem

If azithromycin were used only for its legitimate indications, prescribing volume of this drug would drop by seventy-five to ninety percent, in my estimation. That is not a rounding error. That is the scope of the problem.

The Policy Path Forward

The five-day course still exists because it became woven into the fabric of medical practice: the template, the training, the patient expectation, the path of least resistance. The blister pack, the dosing card, the branded identity: in my view, these were marketing decisions, not pharmacologic ones. The fix: retire the five-day format entirely. Manufacture only 500 mg scored tablets. For the narrow indications that warrant azithromycin at all, the three-day course is the evidence-supported option. A three-day course removes the identity. No more pack. No more reflex. The category ceases to exist in the way it currently does.

R.W. Raskinism

You don't need an antibiotic for a cold. You need a plan.

A cold is a viral illness, not a bacterial infection. Antibiotics don't treat viruses or the symptoms they cause. If you believe you may have a bacterial infection, seek medical evaluation promptly.
References
  1. Kenealy T, Arroll B. Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev. 2025;11:CD000247.
  2. Harris AM, Hicks LA, Qaseem A. Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults. Ann Intern Med. 2016;164(6):425–434.
  3. Mangione-Smith R, McGlynn EA, Elliott MN, McDonald L, Franz CE, Kravitz RL. Parent expectations for antibiotics, physician-parent communication, and satisfaction. Arch Pediatr Adolesc Med. 2001;155(7):800–806.
  4. Ritchie SR, Rakhmanova L, Out-O'Reilly E, Reay S, Thomas MG, Sajtos L. The use of a poster to reduce expectations to receive antibiotics for a common cold. Eur J Clin Microbiol Infect Dis. 2019;38(8):1463–1469.
  5. Payne SC, McKenna M, Buckley J, et al. Clinical Practice Guideline: Adult Sinusitis Update. Otolaryngol Head Neck Surg. 2025;173 Suppl 1:S1–S56.
  6. Global Initiative for Chronic Obstructive Lung Disease. 2026 GOLD Report.
  7. Odeyemi YE, Tekin A, Schanz CC, et al. Comparative Effectiveness of Azithromycin Versus Doxycycline in Hospitalized Patients With Community-Acquired Pneumonia Treated With Beta-Lactams. Clin Infect Dis. 2026;82(4):639–647.
  8. Kim K, Jung S, Kim M, Park S, Yang HJ, Lee E. Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5(7):e2220949.
  9. Munson E, Lavey SC, Lasure MR, Fox BC. Changes in Streptococcus pneumoniae Susceptibility in Wisconsin: Implications for Clinical Treatment Decisions for Respiratory Infections. Clin Med Res. 2022;20(4):185–194.
  10. Smith SM, Fahey T, Smucny J, Becker LA. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2017;6:CD000245.

For informational and educational purposes only. Clinical judgment applies in all patient encounters.